Last reviewed · How we verify
Tegaserod and Polyethylene Glycol 3350 — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Tegaserod and Polyethylene Glycol 3350 (Tegaserod and Polyethylene Glycol 3350) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tegaserod and Polyethylene Glycol 3350 TARGET | Tegaserod and Polyethylene Glycol 3350 | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tegaserod and Polyethylene Glycol 3350 CI watch — RSS
- Tegaserod and Polyethylene Glycol 3350 CI watch — Atom
- Tegaserod and Polyethylene Glycol 3350 CI watch — JSON
- Tegaserod and Polyethylene Glycol 3350 alone — RSS
Cite this brief
Drug Landscape (2026). Tegaserod and Polyethylene Glycol 3350 — Competitive Intelligence Brief. https://druglandscape.com/ci/tegaserod-and-polyethylene-glycol-3350. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab